Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead

Cormedix Inc. ((CRMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Cormedix Inc.’s latest earnings call struck a cautiously balanced tone, pairing record product sales, solid profitability, and strong liquidity with clear warning signs around future reimbursement and customer concentration. Management highlighted successful integration of the Melinta acquisition and a promising late‑stage pipeline, but also acknowledged that DEFENCATH has likely peaked under current reimbursement and faces steep pricing pressure ahead.

Record DEFENCATH Sales Mark Commercial Peak

DEFENCATH delivered net sales of $258.8 million in 2025, described as just under $260 million, making it Cormedix’s largest single‑product revenue contributor to date. Management framed 2025 as a commercial high‑water mark for DEFENCATH before reimbursement changes begin to erode pricing and volumes over the next two years.

Melinta Acquisition Adds Scale and Synergies

Cormedix closed its acquisition of Melinta Therapeutics on August 29, 2025 and reported that the combined company fully realized its targeted $35 million in annual cost synergies during the year. Melinta contributed $37.4 million of revenue in the fourth quarter, underscoring its role as a meaningful second growth pillar alongside DEFENCATH.

Robust Quarterly and Pro Forma Revenue Base

Fourth‑quarter 2025 revenue reached $128.6 million, with DEFENCATH generating $91.2 million and Melinta adding $37.4 million in sales. On a pro forma basis, combining both businesses for the full year, Cormedix reported 2025 revenue of $401.3 million, essentially in line with management’s prior guidance and giving investors a clearer view of the company’s new scale.

Profitability Metrics Validate the Business Model

Adjusted EBITDA for the fourth quarter was $77.2 million, landing within prior guidance and highlighting the earnings power of the combined portfolio. For 2025, Cormedix reported net income of $14.0 million and pre‑tax income of $56.4 million in Q4, an improvement of $43.0 million versus the prior year’s fourth quarter performance.

Liquidity and Cash Generation Remain a Strength

The company closed the fourth quarter with $148.5 million in cash, cash equivalents, and short‑term investments, providing a substantial liquidity buffer heading into a more uncertain reimbursement environment. Operating cash flow was nearly $100 million in the quarter, demonstrating strong cash conversion from earnings, even as management flagged some near‑term working‑capital headwinds ahead.

RIZEAO and TPN Programs Underpin Pipeline Upside

The Phase III RESPECT trial evaluating RIZEAO prophylaxis completed enrollment in September 2025, with database lock expected in March 2026 and top‑line data anticipated in the second quarter of 2026. Management pegged the potential market opportunity for RIZEAO around $2.5 billion across indications, while estimating DEFENCATH in total parenteral nutrition at $500 million to $750 million in annual sales if successful.

NEUTROGUARD Study Progresses but Faces Timing Risk

Cormedix reported that the Phase III NEUTROGUARD study, evaluating DEFENCATH to prevent CLABSI in TPN patients, is about 30% enrolled toward a minimum of 90 patients, with an adaptive design that could extend enrollment up to 200 patients. The company continues to add sites, including in Turkey, and currently expects study completion in early 2027, but acknowledged that timelines will depend on improved enrollment rates.

Workforce Expansion and Integration Support Scale‑Up

Headcount roughly doubled from about 100 to just under 200 employees following the Melinta transaction, reflecting the integration of the two organizations and the build‑out required to support broader commercial efforts. Management also highlighted the launch of an active share repurchase program, signaling confidence in the company’s valuation and future cash generation.

Reimbursement Transition Signals Imminent Price Erosion

On July 1, 2026 DEFENCATH will transition from TDAPA reimbursement to a bundled add‑on mechanism, a change management expects will materially pressure pricing. The company anticipates 2026 DEFENCATH revenue will be heavily front‑loaded in the first half, with notable price erosion by the fourth quarter as the new reimbursement structure takes full effect.

Guided DEFENCATH Revenue Decline From 2025 Peak

Management’s 2026 DEFENCATH revenue guidance of $150 million to $170 million implies a steep drop from 2025’s $258.8 million, with the midpoint suggesting about a 38% year‑over‑year decline. Looking further out, 2027 guidance of $100 million to $125 million, with a midpoint near $112.5 million, points to a roughly 56% decline from the 2025 peak and underscores the impact of reimbursement pressure.

Operating Expenses Surge With Scale and Investment

Fourth‑quarter 2025 operating expenses jumped to $48.2 million from $17.1 million in the same period of 2024, an increase of about 182%. Management attributed the surge to the costs of running a much larger combined organization, merger‑related charges, and stepped‑up investment in late‑stage clinical programs such as RESPECT and NEUTROGUARD.

Customer Concentration Adds Commercial Risk

DEFENCATH volumes remain highly concentrated, with one large dialysis organization and two mid‑sized operators accounting for roughly 90% of total usage. This concentration leaves Cormedix exposed to potential changes in contracts or pricing, as any churn or renegotiation at one of these customers could have outsized effects on revenue during an already challenging reimbursement transition.

Legislative and Reimbursement Outcomes Remain Unclear

Management discussed ongoing efforts to secure more favorable reimbursement treatment for DEFENCATH, including potential extensions or policy adjustments, but emphasized that these processes are uncertain and timing‑dependent. Broader legislative dynamics and geopolitical factors could influence if and when any changes are enacted, leaving investors with limited visibility into the company’s near‑term reimbursement outlook.

Non‑Cash Tax Effects Complicate Earnings Picture

Cormedix’s 2025 net income figure was significantly affected by $42.4 million in tax expense, the majority of which was non‑cash and related to the utilization of deferred tax assets. Management suggested that these accounting impacts complicate a straightforward interpretation of GAAP profitability and encouraged investors to focus on adjusted EBITDA and cash flow metrics.

Near‑Term Cash Flow Faces Working‑Capital Drag

Despite strong fourth‑quarter cash generation, the company flagged potential near‑term cash headwinds from inventory stockpiling to support technology transfers and from the payment of sizable accrued rebates in early 2026. These factors could temporarily dampen operating cash flow even as underlying business economics remain attractive on an adjusted basis.

Guidance and Outlook Emphasize Caution and Optionality

Cormedix reaffirmed 2026 DEFENCATH revenue guidance of $150 million to $170 million and 2027 guidance of $100 million to $125 million, while reiterating 2026 consolidated revenue of $300 million to $320 million and adjusted EBITDA of $100 million to $125 million. Management expects 2026 revenue to be front‑loaded before fourth‑quarter price pressure hits, and believes 2027 net pricing could improve versus the third quarter of 2026 depending on the ultimate reimbursement methodology.

Cormedix’s earnings call painted a picture of a company at a crossroads, with record DEFENCATH sales, solid profitability, and a well‑funded late‑stage pipeline offset by looming reimbursement compression and concentrated customer exposure. For investors, the story now pivots from harvesting a reimbursement‑driven peak to navigating a more challenging revenue trajectory while betting on pipeline catalysts like RIZEAO and NEUTROGUARD to sustain long‑term value.